We have evaluated the feasibility of large-scale isolation of CD133+ progenitors from healthy mobilized adult donors for potential clinical use in autologous and allogeneic transplantation. A total of 11 healthy volunteer adult donors were mobilized with G-CSF. CD133+ stem cells were isolated from a single leukapheresis using the Clinimacs method. The median percentage of CD133 before positive selection was 0.75% (range 0.39-2.03%). After selection, the median purity and recovery was 94% (range 85.2-98.0%) and 69% (range 44-100%), respectively. The median log10 T-cell depletion obtained by CD133+ positive selection was 4.2 (range 3.8-4.7). The CD133+ progenitors were highly enriched in colonyforming units (CFU) and transplantation into NOD/SCID mice resulted in a high engraftment rate. Transplantation of sorted CD133+/CD34+ cells into NOD/SCID mice showed a higher engraftment compared to CD133À/ CD34+ cells. Mobilized peripheral CD133+ stem cells can be purified in large scale for potential clinical use. The biological function of the cells is not impaired. The majority of the NOD/SCID repopulating cells are within the CD133+/CD34+ subpopulation. Therefore, clinical studies using purified CD133+ stem cells can be envisoned to further clarify the role of CD133+ stem cells in hematopoietic reconstitution after transplantation.
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Positive selection of CD34+ stem cells from G-CSF mobilized peripheral stem cells obtained from healthy volunteer donors is increasingly employed in allogeneic matched related, 1 matched unrelated 2 and haploidentical 3 transplantation. The reason for the positive selection of CD34+ stem cells is the indirect depletion of T and B lymphocytes for the prevention of graft-versus-host disease (GvHD) and post-transplant EBV-associated lymphoproliferative disease, respectively. The commonly used methods for clinical large-scale purification of peripheral CD34+ stem cells are magnet-activated cells sorting (Clinimacs) 4 and the Isolex system. 5 Both methods result in a high purity of CD34+ stem cells with a significant indirect depletion of T lymphocytes.
A more recently described antigen for the identification of human hematopoietic stem cells is the AC133 (CD133) antigen. 6 The majority of cells that express CD133 coexpress the CD34 antigen. 7 The CD133 antigen is a five-transmembrane glycoprotein, which is homologous to the murine prominin five-transmembrane glycoprotein PROML 1. 8 The antigen is phylogenetically conserved from mammals to zebrafish, Drosophila and Caenorhabdities elegans. 9 The specific function of CD133 or potential ligands are unknown. CD133 is not only expressed on hematopoietic precursors, but also on circulating cells with endothelial capacity. 10 It has been shown that human CD133+ cells expressing the vascular endothelial growth factor receptor (VEGF-R2) and CD34 might play a role in repair mechanisms during vascular trauma, since these circulating endothelial precursors can be mobilized by chemokines and accelerate the repair of damaged vascular tissue. 11 In addition, CD133+/CD34À/LinÀ stem cells have been described in adult and cord blood. 12 It has been proposed that CD133+/CD34ÀCD38À/LinÀ stem cells give rise to CD34+ cells with hematopoietic and endothelial capacity. 13 Whether CD133+/CD34À/LinÀ stem cells play a role in reconstitution and hematopoietic recovery after allogeneic transplantation is currently unknown, since positively selected CD133+ progenitor cells have not yet been used in allogeneic transplantation.
In this paper, we show that CD133+ stem cells can efficiently be isolated to a high purity from G-CSF mobilized blood stem cells without compromising their biological functions. Further clinical use of purified CD133+ stem cells in allogeneic transplantation, eventually combined with gene-marking studies, should provide more insight into the biology and significance of this stem cell subset.
Materials and methods

Mobilization and collection of PBSCs
PBSCs were mobilized from 11 healthy adult volunteer donors using G-CSF (480 mg/day; Neupogen, Amgen, Thousand Oaks) for 4 days. The median age of the donors was 25 years (range 19-28 years). A single leukapheresis was performed at day 5 using a Cobe Spectra Apheresis system with the Version 6.1 software (Cobe, Lakewood, CO, USA). All PBSC donors had given written informed consent and the study had been approved by the institutional review board.
Positive selection of CD133+ stem cells
PBSCs were processed either immediately or mixed with an equal volume of autologous plasma and stored overnight at 41C. Cells were transferred into a 175 ml conical flask. PBSC were washed once with phosphate-buffered saline (PBS) supplemented with 1 mM EDTA and 0.5% human serum albumin (HSA) and incubated with the anti-CD133 antibody conjugated to magnetic microbeads (clone: AC133, Miltenyi, Bergisch-Gladbach, Germany). Incubation was under continuous agitation at room temperature for 30 min. PBSC were washed twice with PBS/EDTA/ HSA. Cells were centrifuged at 300g for 15 min without brake and resuspended in buffer to a final cell concentration of 1-2 Â 10 8 cells/ml. Cells were transferred to the cell separation bag using a 60 ml syringe and 16G needle and then processed with the fully automated Clinimacs device (Miltenyi) equipped with TS separation columns using the program 'Enrichment 2.1' according to the manufacture's instruction.
Flow cytometric analysis and cell sorting
The percentage of human CD45+, CD133+, CD3+, CD14+, CD19+, CD34+ and CD56+ and murine-CD45+ cells was determined using antibodies labeled either with fluoresceinisothiocyanate (FITC) or phycoerythrin (PE). The anti-CD133 antibody conjugated to PE (clone: AC133/2 (293C3)) was obtained from Miltenyi, all other antibodies were from Becton-Dickinson (Mountainview, CA, USA). Clone AC133/2 (293C3) recognizes epitope 2 and does not overlap with clone AC133 used in the selection. Flow cytometric analysis was performed using a flow cytometer (LSR, Becton-Dickinson). Briefly 1 Â 10 6 unselected cells or 0.1-0.5 Â 10 6 CD133 enriched cells were incubated for 10 min at room temperature with saturating amounts of antibodies. Subsequently, red cells were lysed (ammonium chloride cell lysis buffer) and washed twice with PBS. Data acquisition and analysis was performed on a three-laser LSR (Becton-Dickinson) flow cytometer using CellQuest software.
For the cell sorting experiments, CD34+ stem cells were first purified with the Clinimacs system (MiltenyiBiotec) and then sorted into CD133+/CD34+ and CD133À/ CD34+ subsets using a FacsVantage fluorescence-activated cell sorter with pressure set at 30 psi, a flow rate of 6000 cells/s and an aperture size of 70 mm. Cell recovery after sorting was 70%.
Colony-forming unit (CFU) assays
Purified CD133+ cells obtained from four donors (donors two to five) were plated at 1000 cells/plate in methylcellulose-based semisolid culture medium-MethoCult H4433 (Stem Cell Technologies Inc., Vancouver, Canada). After 14 days, total numbers of colonies were counted and scored for the presence of burst-forming units-erythroid (BFU-E), colony-forming units-granulocyte/macrophage (CFU-GM) and colony-forming unit-granulocyte erythrocyte/macrophage/megakaryocyte (CFU-GEMM). Assays were performed in triplicates.
NOD/SCID repopulation assays
NOD/SCID mice (NOD.CB17-Prkdc scid /J, Jackson Laboratory, Bar Harbor, USA) were irradiated with 325 cGy using a 137 Cs source (JL Shepherd Inc., CA, USA). Cells were resuspended in 500 ml PBS and mice were injected into the lateral tail vein with purified CD133+ stem cells at doses of 1 Â 10 6 , 0.5 Â 10 6 or 0.25 Â 10 6 per mouse or with 0.5 Â 10 6 and 0.1 Â 10 6 sorted CD133+34+ and CD133À34+ cells. Mice were killed after 8 weeks and the bone marrow was harvested by flushing femora and tibiae. Human engraftment was determined by double staining the BM cells with a directly labeled anti-human CD45 antibody and an anti-murine CD45 antibody (both Becton-Dickinson). Percentage engraftment was determined as the ratio of the number of bone marrow cells staining positive for anti-human CD45 to the number of cells staining positive for anti-human and anti-mouse CD45.
Detection of human engraftment by PCR
Bone marrow cells from transplanted mice were flushed from marrow. DNA was extracted with the QIAamp DNA purification kit by Qiagen (Stanford, USA). PCR reactions contained 1 Â PCR buffer (Qiagen PCR buffer), 1.5 mM MgCl 2 , 200mM of each deoxynucleotide triphosphate, 0.5 ml (2.5 U) Qiagen HotStarTaq DNA Polymerase, 25 pM of each specific primer, 250 ng template DNA and dH 2 O to make a final reaction volume of 50 ml. The PCR reaction was performed in a Perkin-Elmer 9700 (Perkin-Elmer, Norwalk, CT, USA) and included activation at 951C for 15 min followed by 35 cycles of 941C for 30 s, 601C for 30 s, 721 for 15 s with a final extension at 721 for 3 min. CART-1 primers 5 0 -AAGGA-TACCACAATAAGCTGC-3 0 and 5 0 -GGTTTGTGGA-GACTGGCAC-3 0 were used, which amplifies a 156-basepair product from the untranslated region of the human CART-1 gene and fails to amplify a product from mouse genomic DNA.
Results
Positive selection of CD133+ progenitors
From the 11 mobilized donors, a median number of 1.3 Â 10 10 (range 0.70-3.8 Â 10
10
) mononuclear cells was obtained with a median percentage of CD133+ cells of 0.75% (range 0.39-2.03%). After positive selection, the median number of isolated CD133+ cells was 74.2 Â 10 positive cells was 94% (range 85.2-98.0%) and the median recovery was 69% (range 44-100%). These data are summarized in Table 1 . In Figure 1 , a representative twocolor flow cytometric analysis before (a) and after (b) CD133+ positive selection is shown. In addition, the percentage of CD3+ T lymphocytes and CD19+ B lymphocytes was measured before (c) and after CD133 selection (d). Before positive selection, the median percentage of CD3+ T lymphocytes was 60.1% (range 45.1-84.1%). After CD133 selection, the median percentage of residual CD3+ T lymphocytes was 0.68% (range 0.30-1.58%). This represents a median log10 T-cell depletion of 4.2 (range 3.8-4.7). In addition, the median percentage of C19+ B-cells, CD14+ monocytes and CD56+ natural killer (NK) cells was determined after CD133+ positive selection and was 2.7% (range 1.12-10.7%), 2.02% (range 0.42-3.15%) and 0.22% (range 0.05-0.42% ), respectively. These data are summarized in Table 2 . Table 1 Number of mononuclear cells (MNC) before selection, percent of CD133+ cells before and after and total number and percent recovery of CD133 cells after positive selection 
Functional in vitro and in vivo assays
In order to exclude positive selection of CD133+ stem cells, using an anti-CD133 monoclonal antibody conjugated to magnetic microbeads, having any negative impact on the biological function of the CD133+ stem cells, in vitro colony-forming assays and in vivo NOD/SCID repopulating assays were performed. For the colony assays, 1 Â 10 3 CD133+ cells obtained after positive selection from donors two to five were plated and colonies were scored after 14 days. As shown in Table 3 , the CD133+ cells after Clinimacs selection were highly enriched in CFU. The median number of total colonies per 1 Â 10 3 plated cells was 358 (range 257-371). The most prominent types of colony were CFU-GM followed by CFU-GEMM and BFU-E. In order to see the contribution of CD133+/CD34+ and CD133À/CD34+ stem cell subsets to the in vitro colony formation, these subsets were sorted to purity 498% and plated in the colony assay. Sorting was done in two donors, from whom enough CD133+ cells were available for these experiments (donors six and seven). The CD133+CD34À population was consistently less than 1% or hardly detectable at all and therefore this population was not sorted. Whereas the CD133+/CD34+ stem cells from these two donors were highly enriched in CFU-GEMM and CFU-GM, the CD133À/CD34+ stem cells were mainly enriched in erythroid progenitors, since plating of this subset mainly resulted in the formation of BFU-E (Figure 2 ).
Owing to the limitations of the in vitro CFU assay for the evaluation of primitive hematopoietic progenitors, we have additionally investigated the NOD/SCID repopulating activity of the positively selected CD133+ stem cells. ) of CD133+ stem cells obtained after Clinimacs positive selection were injected into NOD/SCID mice. Mice were sacrificed after 8 weeks and the engraftment of human cells was assessed in the bone marrow of the mice by staining with human anti-CD45 antibodies. In all experiments, a high engraftment potential of the CD133+ stem cells could be observed. These data are summarized in Figure 3 . We were then interested in the contribution of CD133+/CD34+ and CD133À/CD34+ progenitors to the NOD/SCID engraftment. Whereas the transplantation of CD133+/CD34+ cells resulted in a high degree of engraftment, CD133À/CD34+ progenitors contributed much less to engraftment. In mice grafted with CD133+/ CD34+ obtained from donor seven, engraftment could be seen in four out of four mice by flow cytometry, whereas in four mice transplanted with CD133À/CD34+ cells no engraftment could be seen (Figure 4a) . In another donor (donor six), a higher engraftment indicated by a stronger PCR signal for CART-1 was seen in five out of five mice with the CD133+/CD34+ subset, whereas a lower signal was obtained in four out of four mice transplanted with CD133À/CD34+ progenitors (Figure 4b ). These data suggest that the progenitors responsible for the NOD/ SCID engraftment are enriched in the CD133+/CD34+ stem cell subset.
Discussion
The use of highly purified progenitor cells offers some advantages in both autologous and allogeneic transplantation. Currently, the CD34+ antigen is widely used to purify hematopoietic progenitors in the clinical setting. In the autologous situation, it offers rapid and effective purging of malignant cells that do not coexpress the CD34+ antigen. However, there might be malignancies that coexpress the CD34+ antigens, such as acute lymphoblastic leukemia.
14 In such cases, the CD133+ antigen could be used for purging, given that the malignant cells do not coexpress the CD133 antigen. In such a clinical setting, highly purified CD133+ mobilized peripheral stem cells have already been successfully used in autologous transplantation of a patient with ALL. 15 In addition, isolated CD133+ cells have already been used in few patients with lymphoma (A. Tabilio, personal communication). All patients showed a rapid and complete hematopoietic reconstitution after myeloablative therapy. However, the follow-up of these patients is still too short to evaluate the capacity of the CD133+ stem cells to induce long-term hematopoiesis.
In the allogeneic setting, the role of CD133+ stem cells in transplantation compared to the use of CD34+ cells is not yet clear. The rationale for using purified stem cells in allogeneic transplantation is the indirect depletion of T and B lymphocytes to avoid GvHD and post-transplant EBV-LPD. It has been demonstrated by us and others that this can be achieved in matched unrelated 2 and in three-locus mismatched haploidentical transplantation. 3, 16 By positive selection of CD34+ progenitors, T-cell depletion is 45 log. This highly effective T-cell depletion is achieved because of the high purity of the CD34+ stem cells after positive selection. 4 Compared to the CD34+ positive selection, the median purity of the CD133+ stem cells after positive selection with Clinimacs was slightly lower (94%) with a median T-cell depletion of 4.2log, which is lower than the T-cell depletion obtained with CD34+ selection and Clinimacs. However, this T-cell depletion is still higher than that obtained with negative depletion techniques (for review, see Ho and Saiffer 17 ). The median recovery of CD133+ cells after positive selection was 69%, which is quite similar to that seen after CD34+ selection.
The positive selection process using the Clinimacs device did not impair the biological function of the cells. As shown in Table 3 , the median number of colonies per 1000 CD133+ was 358 (range 257-371). The most prominent colony type was CFU-GM followed by CFU-GEMM and BFU-E. In addition, the purified CD133+ cells showed a high engraftment rate in NOD/SCID mice. Most of the NOD/SCID engrafting cells are contained in the CD133+ population, since the CD133À/CD34+ subset had a much lower capacity to reconstitute NOD/SCID mice.
The existence of CD34À stem cells capable of giving rise to CD34+ cells and to engraft NOD/SCID mice has been described. 18 The biological significance of this subset is currently unclear. In cord blood, a rare CD133+/CD34À/ CD38À/LinÀ stem cell population was isolated. 12 This population showed CFC capacity equal to that of CD34+/ CD38À/LinÀ. After a short term in vitro cultivation of this population, they acquired CD34 antigen expression. In addition, NOD/SCID engraftment of de novo isolated or ex vivo cultured CD133+/CD34À/CD38À/LinÀ cells was observed. These data suggest that CD133+/CD34À stem cells are early hematopoietic progenitors and that this subset precedes the CD133+/CD34+ subset. 13 In our experience with adult mobilized donors, there is a tremendous individual variability concerning the presence of a circulating CD133+/CD34À subset and in most of the donors, we were not able to identify a distinct subpopulation. It could well be that this subset is below the detection limit of flow cytometry. The potential contribution of this small CD133+/CD34À subset in a transplant setting is not known. It might well be that the inclusion of this subset in the graft in a clinical transplant setting might be advantageous compared to the use of CD34+/CD133+ and CD34+/CD133À stem cells. However, further studies should give information concerning the significance of this subset.
In summary, we demonstrate that mobilized peripheral CD133+ stem cells from healthy donors can be purified in a large-scale approach. The biological in vitro and in vivo function of the cells is not impaired. Therefore, clinical studies can be envisioned to further clarify the participation of CD133+ stem cells in hematopoietic reconstitution after transplantation.
